SCHEMBL2676134

SCHEMBL2676134

Cc1c(C(=O)O)c2cccc(C(F)(F)F)c2c(=O)n1-c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.45
GFER P55789 1/20 0.45
KDM4E B2RXH2 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
MAPT P10636 2/20 0.44
ATM Q13315 1/20 0.44
NOTUM Q6P988 3/20 0.44
CNR1 P21554 2/20 0.44
CNR2 P34972 2/20 0.44
ALDH1A1 P00352 2/20 0.43
PIK3CD O00329 1/20 0.41
PIK3R2 O00459 1/20 0.41
PIK3CG P48736 1/20 0.41
NPSR1 Q6W5P4 1/20 0.39
RORC P51449 3/20 0.38
TAS2R14 Q9NYV8 1/20 0.37
PTGFR P43088 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3631255 0.90 L3MBTL1 (0.46) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL2677224 0.83 GAA (0.48) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL1718661 0.83 GAA (0.50) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL2677436 0.81 GAA (0.51) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL1036361 0.81 RORC (0.51) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL1717651 0.80 TACR3 (0.43) ATMALDH1A1PIK3CDPIK3R2PIK3CG
SCHEMBL1717212 0.79 MAPT (0.60) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL1718433 0.78 GAA (0.60) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL1718143 0.78 GAA (0.45) GAAGFERKDM4EL3MBTL1MAPT
SCHEMBL31502950 0.77 GAA (0.46) GAAGFERKDM4EL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US claimed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP claimed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US claimed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO claimed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. Lundbeck A/S (DK) 2010-02-10 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 GAA 2229/4885GFER 3896/4885KDM4E 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.